Evercore ISI analyst Gavin Clark-Gartner lowered the firm’s price target on Dyne Therapeutics (DYN) to $41 from $46 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a “notable lengthening” of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics’ DYNE-251 Study Update: A Potential Game-Changer for Duchenne Muscular Dystrophy
- Dyne Therapeutics Announces $200M Public Offering
- Morning Movers: Tesla dips as Musk and Trump resume feud
- Dyne Therapeutics 24.2M share Spot Secondary priced at $8.25
- Closing Bell Movers: Progress Software slips 4% after earnings